Article
CTLA-4 inhibitors drive colitis through metabolic reprogramming-mediated Treg/Th17 imbalance
2026-01-21
Abstract excerpt
Immune checkpoint inhibitors (ICIs), especially CTLA-4 inhibitors (αCTLA-4), exhibit a high incidence of colitis as an immune-related adverse event (irAE) during cancer treatment, severely limiting patient benefit. Clinically, both treatment interruption and existing intervention drugs for ICI-mediated colitis may compromise antitumor efficacy. However, there is inadequate research on the pathogenesis of ICI-media...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 1f16aae2-0ade-536c-9efa-999a1a65f1c8
- DOI
- 10.64898/2026.01.20.700699
